NASDAQ$ZBIO
Zenas Biopharma Inc · Q1 2025 earnings
Q1 2025 earnings ·
Briefing
Zenas BioPharma reported Q1 2025, revenue of $10M, net loss of $33.6M, diluted EPS of $-0.80.
For Q1 2025, Zenas BioPharma reported revenue of $10M, a net loss of $33.6M, diluted EPS was $-0.80. Management discusses operating trends, capital, and sector risks in the quarterly filing.
- Q1 2025 revenue $10M.
- Net loss $33.6M.
- Diluted EPS $-0.80.
Headline financials
Revenue & EPS history
Zenas Biopharma Inc · Revenue · Quarterly
$10M
Forward guidance
Clinical-stage biotech filers emphasize trial milestones, regulatory paths, and cash runway; product revenue is limited or absent.
Tailwinds
- Pipeline progress and partnership optionality.
- Cash balances funding operations into upcoming catalysts.
- Regulatory designations where applicable.
Headwinds
- Trial failure or regulatory delay risk.
- Dilution from equity raises.
- No near-term product revenue for most programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 4 quarterly earnings reports · overlaid with Q1 2025
+4.3%
Avg return
Earnings day
+3.2%
Avg return
5 days after
+3.2%
Avg return
30 days after
80%
4 / 5 earnings
Positive
+12.2%
Q1 2025
Best reaction
-3.1%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.9% | -11.7% | +3.0% | |
| Q3 2025 | +1.7% | +1.9% | +15.3% | |
| Q2 2025 | +6.7% | +12.8% | +35.3% | |
| Q1 2025 | +12.2% | +32.3% | +19.0% | |
| Q3 2024 | -3.1% | -19.6% | -56.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro